Justin Ferdinandus

#EarlyCareer Physician Scientist @UKKoeln 🇩🇪 with interest in Lymphoma 🩸and oncologic imaging 📸during the day | Guitarist 🎸at night

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH24 | Justin Ferdinandus @jusferdinandus @UKKoeln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS 90.8%.
Follow our live feed for more updates: https://t.co/3jV5VRRU2W
#lymsm #lymphoma #MedicalCongress

[Justin Ferdinandus @jusferdinandus]

@jryckman3 It seems the objective globally has shifted towards eliminating RT from 1st line HL protocols, which I personally disagree with given the risk-benefit ratio of modern RT… But I may be biased, as I am married to a RadOnc 👀

[Justin Ferdinandus @jusferdinandus]

@jryckman3 Thanks for raising a lot of important comments ;-) I can promise that dedicated analyses of RT details including QA in HD21 are underway although RT was not a primary focus of the trial and as pointed out performed as per SOC (guided by panel recommendation).

[Blood Cancer Talks @BloodCancerTalk]

New Episode! Tune in for #ASCO24 #EHA24 #Lymphoma updates with @gloria_iacoboni, where we discuss:
STARGLO
ECHO
HD-21
EPCORE-NHL 5
EPCOR-CLL 1
and more!
https://t.co/rqrovKmUXq
@Eddie_Cliff
Check out this short clip on critical appraisal of STARGLO results!
#lymsm

[Justin Ferdinandus @jusferdinandus]

Full text: https://t.co/a1IZoBUf0g

[Justin Ferdinandus @jusferdinandus]

🚨 HD21 results now finally published in the @TheLancet : BrECADD is better tolerated and more efficient than eBEACOPP as PET-guided treatment for patients with adv. Hodgkin Lymphoma! #lymsm

[Justin Ferdinandus @jusferdinandus]

@B_von_Tresckow @BroeckelmannPJ @Dr_Daniel_Molin @HallekMichael @ALLGtrials @UKKoeln @UniCologne

[Sirpa Leppa @LeppaSM]

Top quality session with great speakers on Hodgkin lymphoma at @EHA_Hematology 2024 just started.

[Graham Collins @graham74GC]

Ferdinandus - gondal recovery in HD21
- 80% of ITT pts assessed
- FSH recovery & parenthood rate
- Recovery after BrECADD much better than after eBEAOCPP for men & women (& parenthood)
- But still effect of cycle no. & age
v encouraging data for our pts.
#EHA2024 #lymsm

[Justin Ferdinandus @jusferdinandus]

I just can’t recommend #CRTH highly enough. Apply now, thank me later! Huge thanks to @EHA_Hematology for creating this platform.

[European Hematology Association @EHA_Hematology]

Going from #CRTH scholar to faculty, @DottorClaudio talks about his experience following the program and what new scholars can expect. Tune in soon for the full video.
The call for Clinical Research Training in hematology is now open: https://t.co/LEELh70Lqx

[Justin Ferdinandus @jusferdinandus]

If you are at #EHA2024 in sunny madrid and interested in HL and PROs come see me at our poster on HRQoL between BrECADD and eBEACOPP. ✌🏽 #lymsm

[Justin Ferdinandus @jusferdinandus]

@frbertoni @CascioneLuciano @IOR_Bellinzona @USI_en @EnteOspedaliero @ISBSIB Congratulations! Hoping to see a revival of radionuclide therapy in lymphoma. :-)

[Justin Ferdinandus @jusferdinandus]

@vadim_lesan @majorajay That is usually correct, but infact not true for HL ;-) 90% vs. 95% roughly translates to HR 2.0. At least in my opinion 5% is not a school bus. It is therefore already very tough to run NI-trials in HL. Keep in mind HD21 had to recruit 1500 pts for this NI-margin.

[Justin Ferdinandus @jusferdinandus]

@majorajay @prp_diciaccio Sure! Roughly speaking, childbirth rates among all women receiving BrECADD are very similar to ABVD-treated (i.e. PET2-neg, no relapse) women in RATHL. Stay tuned, as I’ll be discussing HD21 fertility in depth soon at EHA24 ✌🏽

[Justin Ferdinandus @jusferdinandus]

@majorajay @priyankapophali @eha24 C30, FA12 (knowing fatigue is a long-term problem in HL) and a more general „life situation“ questionnaire. In future trials, we are implementing PRO-CTCAE to assess side effects more accurately.

[Justin Ferdinandus @jusferdinandus]

@dgermain21 Yes, absolutely they can (no day 8 infusions with BrECADD - so quite a long break from infusions)! Others back to work very early. But keep in mind that socioeconomic variables (including social insurance) heavily influence work rates. Is there data on sick leave with Nivo-AVD?

[Alex Rampotas @ARampotas]

I can't recommend highly enough this amazing opportunity for training in clinical trial design and delivery by @EHA_Hematology

Being part of the #CRTH24 cohort has been a fantastic experience so far

Do apply below with a clinical trial idea ⬇️⬇️⬇️

https://t.co/9lk1jSRKnX

[Justin Ferdinandus @jusferdinandus]

@graham74GC @alex_epi_tria Exactly, we need to limit unnecessary exposure through individualised treatment. That being said, there are just 160 mg/m2 in 4x BrECADD ;-)